Skip to main content
Berry Genomics Co.,Ltd logo

Berry Genomics Co.,Ltd — Investor Relations & Filings

Ticker · 000710 ISIN · CNE000000PN7 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,009 across all filing types
Latest filing 2019-11-19 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000710

About Berry Genomics Co.,Ltd

https://www.berrygenomics.com

Berry Genomics Co.,Ltd. is a biotechnology enterprise specializing in clinical genomics and genetic testing services. The company focuses on the research, development, and commercialization of genomic technologies for clinical applications. Its core portfolio includes non-invasive prenatal testing (NIPT), utilizing high-throughput sequencing to screen for chromosomal abnormalities. Beyond reproductive health, the company provides genomic solutions for oncology diagnostics, including early cancer screening and companion diagnostics, as well as testing for hereditary diseases. Berry Genomics leverages advanced sequencing platforms and proprietary bioinformatics pipelines to deliver precision medicine tools to healthcare providers and research institutions. The company is recognized for its role in the clinical application of Next-Generation Sequencing (NGS) and its extensive genomic databases used to enhance diagnostic accuracy and therapeutic outcomes.

Recent filings

Filing Released Lang Actions
关于医疗器械产品完成延续注册的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (1065 characters) from a company about the completion of a medical device product's continued registration, specifically the NextSeq CN500 gene sequencer. It includes details about the registration certificate issued by the National Medical Products Administration and the impact on the company's product line and future operations. There are no financial statements, no detailed financial data, no management discussion of results, nor is it a report or presentation. The document is an official announcement regarding regulatory approval and product registration status. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Investor Presentation. It is not a report publication announcement since it does not mention any report being published or attached. The best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories. Confidence is high due to the clear nature of the announcement and its short length.
2019-11-19 Chinese
2019年第三季度报告正文
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2019 Third Quarter Report" of the company, indicating it is a quarterly financial report. It contains detailed financial data such as total assets, net profit, revenue, cash flow, and other financial indicators for the third quarter of 2019. It also includes management discussion on financial changes, shareholder information, and operational updates. The length of the document (12,691 characters) and the presence of substantive financial data and analysis confirm it is a full interim/quarterly report rather than a brief announcement or a certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). 9M 2019
2019-10-30 Chinese
2019年度业绩预告
Earnings Release Classification · 95% confidence The document is a 2019 annual performance forecast (业绩预告) for the full fiscal year 2019 (January 1 to December 31, 2019). It provides estimated financial results such as net profit and earnings per share, but explicitly states that the data is unaudited and preliminary. It also mentions that detailed financial data will be disclosed in the 2019 annual report. The document length is short (1467 characters) and it is a forward-looking earnings preview rather than a full financial report. This matches the characteristics of an Earnings Release (ER), which is an initial announcement of periodic financial results with key highlights only. It is not a full Annual Report (10-K) or Interim Report (IR) because it lacks comprehensive financial statements and analysis. It is not a Report Publication Announcement (RPA) because it contains substantive financial forecast data, not just a notice of report availability. FY 2019
2019-10-30 Chinese
2019年第三季度报告全文
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2019 Third Quarter Report" of 成都市贝瑞和康基因技术股份有限公司, indicating it is a quarterly financial report. It contains detailed financial data such as consolidated balance sheets, income statements, cash flow statements, and notes on financial performance and changes during the quarter. The length is substantial (15,000 characters), and it includes actual financial statements and analysis, not just an announcement or summary. The presence of quarterly period data and comprehensive financial disclosures aligns with the definition of an Interim / Quarterly Report (IR). Q3 2019
2019-10-30 Chinese
关于董事兼高级管理人员增持计划实施期限届满暨实施结果的公告
Director's Dealing Classification · 95% confidence The document is an announcement regarding the completion and results of a share increase plan by a company's director and senior management (ZHOU DAIXING). It details the number of shares purchased, the amount spent, the purpose of the share increase, and compliance with relevant laws and regulations. The document does not contain financial statements or quarterly/yearly financial results but focuses on insider share transactions by a director. This fits the definition of 'Director's Dealing' (DIRS), which covers reports of personal share transactions by company directors and executives (insider trades). The document length is 2135 characters, which is consistent with a detailed announcement but not a full financial report. Therefore, the correct classification is DIRS with high confidence.
2019-10-17 Chinese
关于持股5%以上股东进行股票质押式回购交易补充质押暨延期购回的公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement regarding a shareholder holding more than 5% of shares conducting a stock pledge repurchase transaction, including supplementary pledges and extension of repurchase. It details the number of shares pledged, pledge start and end dates, pledgee, and the proportion of shares pledged. The document also clarifies that the pledge does not affect control of the company and discloses risk information. This type of announcement fits the category of Transaction in Own Shares (POS), as it relates to share pledges and repurchase transactions by a significant shareholder. The document length is short and it is not a full financial report or earnings release, nor a regulatory filing or voting announcement. Therefore, the best classification is POS with high confidence.
2019-10-17 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.